Table 5.
Asthma progression (measured as the intensity of asthma medication use) in the SLIT and non‐AIT groups over the follow‐up period: regression coefficients; 95% confidence intervals (CI) and P‐values of the factors included in the linear regression model
| Factors | Regression coefficient | 95% CI | P‐value |
|---|---|---|---|
| Treatment period | |||
| Intercept | 1.319 | 1.090‐1.548 | <.001 |
| SLIT treatment (vs control) | −0.206 | −0.351 to −0.061 | .005 |
| Age <18 y (vs age 18+ y) | 0.012 | −0.060 to 0.085 | .743 |
| Male (vs unknown) | −0.031 | −0.078 to 0.016 | .198 |
| Female (vs unknown) | −0.029 | −0.075 to 0.016 | .202 |
| ENT specialist (vs GP) | −0.202 | −0.246 to −0.158 | <.001 |
| Dermatologist (vs GP) | −0.101 | −0.256 to 0.055 | .205 |
| Pneumologist (vs GP) | 0.246 | 0.167‐0.325 | <.001 |
| Paediatrician (vs GP) | 0.039 | −0.066 to 0.145 | .465 |
| Internal specialist (vs GP) | −0.014 | −0.069 to 0.042 | .633 |
| Other speciality (vs GP) | 0.004 | −0.155 to 0.164 | .958 |
| Number of years SLIT treatment (p.a.) | 0.009 | −0.103 to 0.121 | .876 |
| Level of AR treatment before index | −0.025 | −0.031 to −0.018 | <.001 |
| Follow‐up period | |||
| Intercept | 0.349 | 0.172‐0.526 | .000 |
| SLIT treatment (vs control) | −0.167 | −0.279 to −0.055 | .004 |
| Age <18 y (vs age 18+ y) | −0.171 | −0.227 to −0.115 | <.001 |
| Male (vs unknown) | −0.108 | −0.144 to −0.072 | <.001 |
| Female (vs unknown) | −0.088 | −0.123 to −0.053 | <.001 |
| ENT specialist (vs GP) | −0.047 | −0.081 to −0.013 | .007 |
| Dermatologist (vs GP) | −0.174 | −0.294 to −0.053 | .005 |
| Pneumologist (vs GP) | 0.005 | −0.057 to 0.066 | .881 |
| Paediatrician (vs GP) | −0.003 | −0.084 to 0.079 | .951 |
| Internal specialist (vs GP) | 0.005 | −0.038 to 0.048 | .818 |
| Other speciality (vs GP) | 0.036 | −0.088 to 0.159 | .570 |
| Number of years SLIT treatment (p.a.) | 0.091 | 0.005‐0.178 | .039 |
| Level of AR treatment before index | 0.004 | −0.001 to 0.009 | .082 |
| Full analysis period (treatment+follow‐up) | |||
| Intercept | 0.446 | 0.286‐0.605 | <.001 |
| SLIT treatment (vs control) | −0.126 | −0.227 to −0.025 | .014 |
| Age <18 y (vs age 18+ y) | −0.145 | −0.196 to −0.094 | <.001 |
| Male (vs unknown) | −0.096 | −0.129 to −0.063 | <.001 |
| Female (vs unknown) | −0.080 | −0.112 to −0.049 | <.001 |
| ENT specialist (vs GP) | −0.078 | −0.109 to −0.047 | <.001 |
| Dermatologist (vs GP) | −0.161 | −0.269 to −0.053 | .004 |
| Pneumologist (vs GP) | 0.058 | 0.003‐0.114 | .038 |
| Paediatrician (vs GP) | 0.004 | −0.070 to 0.077 | .923 |
| Internal specialist (vs GP) | −0.002 | −0.041 to 0.036 | .909 |
| Other speciality (vs GP) | 0.032 | −0.079 to 0.143 | .574 |
| Number of years SLIT treatment (p.a.) | 0.132 | 0.054‐0.210 | .001 |
| Level of AR treatment before index | 0.000 | −0.004 to 0.005 | .963 |
AIT, allergen immunotherapy; AR, allergic rhinitis; SLIT, sublingual immunotherapy.